IL2 and neoplasm: A study has used CRISPR/Cas9 gene editing technology to knock out or inhibit IL-2-induced T cell kinases, and found that it can significantly reduce CAR-T cell failure, promote the formation of memory CAR-T cells, prolong the survival time of CAR-T cells in vivo, and ultimately improve tumor treatment efficacy (88).